Pharmaceutical News

RSS

FDA approves Theravance's VIBATIV for treating complicated skin and skin structure infections

Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved VIBATIV™ (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.

14 Sep 2009

Clinical study results of DAS181 against H1N1 influenza presented

NexBio, Inc. announced today the presentation of two studies of DAS181 activity against H1N1 influenza and NAI-resistant influenza at the 2009 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting on Sunday, September 13, 2009, in San Francisco, CA.

14 Sep 2009

Laquinimod study data reveals its neuroprotective and anti-inflammatory properties

Teva Pharmaceutical Industries Ltd. and Active Biotech today presented data further illuminating the novel, dual mechanism of action (MOA) of investigational oral, once-daily, laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS), conferring neuroprotective and anti-inflammatory properties.

14 Sep 2009

Naproxcinod clinical study results presented at the 2009 World Congress on Osteoarthritis

NicOx S.A. today announced that it has made three scientific presentations at the 2009 World Congress on Osteoarthritis (annual congress of the Osteoarthritis Research Society International - OARSI), which was held from September 10 to 13 in Montreal, Canada.

14 Sep 2009

Sanofi-aventis and Regeneron Pharmaceuticals discontinue Phase 3 trial of aflibercept

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. today announced the discontinuation of the Phase 3 trial that evaluated aflibercept (VEGF Trap) plus gemcitabine versus placebo plus gemcitabine for the first-line treatment of metastatic pancreatic cancer (VANILLA), based on the recommendations by an Independent Data Monitoring Committee (IDMC).

14 Sep 2009

First FOSAMAX case declared as mistrial by the U.S.District Court Judge

Merck & Co., Inc. said today that a mistrial was declared by U.S. District Court Judge John F. Keenan in Boles v. Merck, the first FOSAMAX case to go to trial. This case was the Plaintiffs’ Steering Committee's first choice to take to trial. The Boles case was tried in New York federal court and involved a Florida woman who blamed her dental and jaw problems on FOSAMAX.

14 Sep 2009

Results further support the benefits of TYSABRI for multiple sclerosis patients

Biogen Idec and Elan Corporation, plc (NYSE: ELN) today announced six-month results of an ongoing, one-year longitudinal, observational, patient-reported outcomes study showing multiple sclerosis (MS) patients taking TYSABRI- (natalizumab) experienced an improvement in both their physical function and psychological well-being.

14 Sep 2009

Reme-Flu secured as trade name for Nuvilex's homeopathic flu remedy

Nuvilex, Inc., announced today that Legacy Biotechnologies, Inc., its joint venture partner, has informed the company that Reme-Flu has been secured as the trade name for its homeopathic remedy for helping to prevent and treat flu-like symptoms resulting from influenza, including swine flu.

14 Sep 2009

Mellow Hope completes MEVAC-A tender for Bangladesh

HTDS company is pleased to announce that its China based operating subsidiary Mellow Hope has successfully completed and delivered on its tender for Mevac-A for the country of Bangladesh.

14 Sep 2009

FDA releases latest listing of consumer health information updates

The U.S. Food and Drug Administration today released its latest listing of consumer health information updates. All articles can be accessed from the agency's Web page for consumers at http://www.fda.gov/ForConsumers/default.htm.

14 Sep 2009

TCAD therapy shows potency against seasonal and novel H1N1 influenza viruses

Adamas Pharmaceuticals, Inc., a privately held company, announced today that a multi-center in vitro study of its proprietary triple combination antiviral drug (TCAD) therapy showed substantially greater potency against seasonal and novel H1N1 influenza viruses than currently recommended single or double therapy and that the triple combination is active against drug-resistant flu strains.

14 Sep 2009

FAB Pharma to develop new class of anti-MRSA drugs

FAB Pharma today announced the completion of a €2.3 million round of series A funding led by CDC innovation and co-led by Bioam Gestion.

14 Sep 2009

Marketing study conducted to investigate decline in Gardasil vaccine supply

Sales of Merck's HPV vaccine, Gardasil, declined by a third this year, and three years after the FDA approved the drug an estimated three out of four women remain unvaccinated -- despite millions spent on advertising and lobbying for government mandates. A recent marketing study offers a reason.

14 Sep 2009

Signum Biosciences awarded $1.6 million SBIR Phase II grant

Signum Biosciences, Inc has been awarded a $1.6 million Small Business Innovation Research (SBIR) Phase II grant by the National Institute of Allergy and Infection Diseases (NIAID) to continue the development of its topical STM (Signal Transduction Modulator) anti-inflammatory technology for the treatment of inflammatory skin disease.

11 Sep 2009

IRIN examines report on varying cost of ARVs for countries with similar socioeconomic status

IRIN examines a recent report (.pdf) that found varying price rates countries pay for antiretrovirals (ARVs) - with "some nations … paying up to three times more for the life-prolonging medicines than others with similar HIV prevalence and income levels."

11 Sep 2009

FDA accepts Merz Pharmaceuticals' premarket approval application for Belotero Balance

Merz Pharmaceuticals, LLC, a leading specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Merz's premarket approval (PMA) application for Belotero(R) Balance.

11 Sep 2009

Flu Clinic Locator makes it easy for people to locate the most convenient clinic to get their seasonal flu vaccine

The American Lung Association is making it easier for people to get their seasonal flu vaccine this year with the availability of its 2009-2010 Flu Clinic Locator. The largest online directory of public seasonal influenza vaccination clinics is now available at www.flucliniclocator.org.

11 Sep 2009

Bioneutral's broad spectrum antimicrobial eradicates the H1N1 swine flu virus

BioNeutral Group, Inc. (“BioNeutral”) (OTCBB:BONU), a specialty chemical technology based Life Science Company, announced today that independent lab test results conducted at Microbiotest Inc. of Sterling, Virginia, demonstrated that Ygiene® antimicrobial diluted 1 to 10 with water can totally eradicated the H1N1 Swine Flu virus in 59 seconds on an unclean, soiled surface.

11 Sep 2009

Federal court's approval clears the way for pricing rollback of pharmaceutical drugs

Purchasers of pharmaceutical drugs including consumers and health plans will soon enjoy a rollback of benchmark prices of some of the most common prescription medications after a Federal Appeals Court last week affirmed the approval of a settlement with two leading drug-pricing publishers, First DataBank, Inc. and Medi-Span, a division of Wolters Kluwer Health, Inc.

11 Sep 2009

Oculus Innovative Sciences Receives Medicare HCPCS Code For Reimbursement Of Microcyn® Skin & Wound Hydrogel

Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, announced today that Noridian Administrative Services LLC, which is the pricing, data analysis and coding contractor for the Medicare program with respect to durable medical equipment, prosthetics, orthotics, and medical supplies, has assigned a Medicare HCPCS code for Oculus’ recently introduced Microcyn Skin & Wound HydroGel.

11 Sep 2009

Pharmaceutical News

FDA approves Theravance's VIBATIV for treating complicated skin and skin structure infections

Clinical study results of DAS181 against H1N1 influenza presented

Laquinimod study data reveals its neuroprotective and anti-inflammatory properties

Naproxcinod clinical study results presented at the 2009 World Congress on Osteoarthritis

Sanofi-aventis and Regeneron Pharmaceuticals discontinue Phase 3 trial of aflibercept

First FOSAMAX case declared as mistrial by the U.S.District Court Judge

Results further support the benefits of TYSABRI for multiple sclerosis patients

Reme-Flu secured as trade name for Nuvilex's homeopathic flu remedy

Mellow Hope completes MEVAC-A tender for Bangladesh

FDA releases latest listing of consumer health information updates

TCAD therapy shows potency against seasonal and novel H1N1 influenza viruses

FAB Pharma to develop new class of anti-MRSA drugs

Marketing study conducted to investigate decline in Gardasil vaccine supply

Signum Biosciences awarded $1.6 million SBIR Phase II grant

IRIN examines report on varying cost of ARVs for countries with similar socioeconomic status

FDA accepts Merz Pharmaceuticals' premarket approval application for Belotero Balance

Flu Clinic Locator makes it easy for people to locate the most convenient clinic to get their seasonal flu vaccine

Bioneutral's broad spectrum antimicrobial eradicates the H1N1 swine flu virus

Federal court's approval clears the way for pricing rollback of pharmaceutical drugs

Oculus Innovative Sciences Receives Medicare HCPCS Code For Reimbursement Of Microcyn® Skin & Wound Hydrogel

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Latest News